As manufacturers invest in clinical development of rare disease therapies, payers are examining disease prevalence estimates and determining reimbursements. In this article published in Life Science Leader, Cécile Matthews, Bhavesh Patel, and Owen Male discuss factors payers are considering for such reimbursements. The authors recently conducted an analysis of 15 rare and ultra-rare disease therapies recently approved in France, Germany, Italy, Spain, the UK, and Japan to better understand the factors payers are now considering for reimbursement of rare disease drugs.
Click here to read the article.
CRA Insights: Blockchain & Crypto
Blockchain technologies are disrupting established industries as well as creating new ones. CRA’s experts bring the rigor of their expertise and credentials to...